Texas Permanent School Fund Corp Has $7 Million Stake in Repligen Co. (NASDAQ:RGEN)

Texas Permanent School Fund Corp cut its holdings in Repligen Co. (NASDAQ:RGENFree Report) by 3.4% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 44,038 shares of the biotechnology company’s stock after selling 1,556 shares during the quarter. Texas Permanent School Fund Corp owned about 0.08% of Repligen worth $7,002,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of the company. CWM LLC raised its holdings in Repligen by 19.3% in the second quarter. CWM LLC now owns 384 shares of the biotechnology company’s stock worth $54,000 after purchasing an additional 62 shares during the period. Zions Bancorporation N.A. raised its holdings in shares of Repligen by 1.0% during the second quarter. Zions Bancorporation N.A. now owns 6,431 shares of the biotechnology company’s stock worth $910,000 after acquiring an additional 63 shares during the period. Fortis Capital Advisors LLC raised its holdings in shares of Repligen by 32.7% during the first quarter. Fortis Capital Advisors LLC now owns 272 shares of the biotechnology company’s stock worth $46,000 after acquiring an additional 67 shares during the period. Robeco Institutional Asset Management B.V. raised its holdings in shares of Repligen by 6.6% during the second quarter. Robeco Institutional Asset Management B.V. now owns 1,284 shares of the biotechnology company’s stock worth $182,000 after acquiring an additional 80 shares during the period. Finally, Signaturefd LLC raised its holdings in shares of Repligen by 44.1% during the third quarter. Signaturefd LLC now owns 281 shares of the biotechnology company’s stock worth $45,000 after acquiring an additional 86 shares during the period. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts recently commented on the stock. Stifel Nicolaus dropped their price objective on shares of Repligen from $200.00 to $165.00 and set a “buy” rating on the stock in a report on Wednesday, November 1st. UBS Group lowered their price target on shares of Repligen from $210.00 to $170.00 and set a “buy” rating on the stock in a research note on Thursday, November 2nd. KeyCorp lowered their price target on shares of Repligen from $240.00 to $210.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 1st. Benchmark lowered shares of Repligen from a “buy” rating to a “hold” rating in a research note on Monday, December 4th. Finally, JPMorgan Chase & Co. lifted their price target on shares of Repligen from $170.00 to $210.00 and gave the company an “overweight” rating in a research note on Wednesday, December 20th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $191.50.

Check Out Our Latest Research Report on RGEN

Repligen Trading Up 0.5 %

Shares of NASDAQ:RGEN opened at $205.00 on Friday. The firm has a 50 day moving average of $179.97 and a 200-day moving average of $165.70. The stock has a market capitalization of $11.45 billion, a PE ratio of 100.99, a PEG ratio of 4.77 and a beta of 1.04. Repligen Co. has a 12 month low of $110.45 and a 12 month high of $208.16.

About Repligen

(Free Report)

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

Featured Articles

Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Co. (NASDAQ:RGENFree Report).

Institutional Ownership by Quarter for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.